Sanket S Dhruva, Guoqian Jiang, Amit A Doshi, Daniel J Friedman, Eric Brandt, Jiajing Chen, Joseph G Akar, Joseph S Ross, Keondae R Ervin, Kimberly Collison Farr, Nilay D Shah, Paul Coplan, Peter A Noseworthy, Shumin Zhang, Thomas Forsyth, Wade L Schulz, Yue Yu, Joseph P Drozda
{"title":"在心脏消融导管评估中使用真实世界数据的可行性:国家卫生技术协调中心评估系统的试验案例。","authors":"Sanket S Dhruva, Guoqian Jiang, Amit A Doshi, Daniel J Friedman, Eric Brandt, Jiajing Chen, Joseph G Akar, Joseph S Ross, Keondae R Ervin, Kimberly Collison Farr, Nilay D Shah, Paul Coplan, Peter A Noseworthy, Shumin Zhang, Thomas Forsyth, Wade L Schulz, Yue Yu, Joseph P Drozda","doi":"10.1136/bmjsit-2021-000089","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To determine the feasibility of using real-world data to assess the safety and effectiveness of two cardiac ablation catheters for the treatment of persistent atrial fibrillation and ischaemic ventricular tachycardia.</p><p><strong>Design: </strong>Retrospective cohort.</p><p><strong>Setting: </strong>Three health systems in the USA.</p><p><strong>Participants: </strong>Patients receiving ablation with the two ablation catheters of interest at any of the three health systems.</p><p><strong>Main outcome measures: </strong>Feasibility of identifying the medical devices and participant populations of interest as well as the duration of follow-up and positive predictive values (PPVs) for serious safety (ischaemic stroke, acute heart failure and cardiac tamponade) and effectiveness (arrhythmia-related hospitalisation) clinical outcomes of interest compared with manual chart validation by clinicians.</p><p><strong>Results: </strong>Overall, the catheter of interest for treatment of persistent atrial fibrillation was used for 4280 ablations and the catheter of interest for ischaemic ventricular tachycardia was used 1516 times across the data available within the three health systems. The duration of patient follow-up in the three health systems ranged from 91% to 97% at ≥7 days, 89% to 96% at ≥30 days, 77% to 90% at ≥6 months and 66% to 84% at ≥1 year. PPVs were 63.4% for ischaemic stroke, 96.4% for acute heart failure, 100% at one health system for cardiac tamponade and 55.7% for arrhythmia-related hospitalisation.</p><p><strong>Conclusions: </strong>It is feasible to use real-world health system data to evaluate the safety and effectiveness of cardiac ablation catheters, though evaluations must consider the implications of variation in follow-up and endpoint ascertainment among health systems.</p>","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2021-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ce/79/bmjsit-2021-000089.PMC8749235.pdf","citationCount":"0","resultStr":"{\"title\":\"Feasibility of using real-world data in the evaluation of cardiac ablation catheters: a test-case of the National Evaluation System for Health Technology Coordinating Center.\",\"authors\":\"Sanket S Dhruva, Guoqian Jiang, Amit A Doshi, Daniel J Friedman, Eric Brandt, Jiajing Chen, Joseph G Akar, Joseph S Ross, Keondae R Ervin, Kimberly Collison Farr, Nilay D Shah, Paul Coplan, Peter A Noseworthy, Shumin Zhang, Thomas Forsyth, Wade L Schulz, Yue Yu, Joseph P Drozda\",\"doi\":\"10.1136/bmjsit-2021-000089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To determine the feasibility of using real-world data to assess the safety and effectiveness of two cardiac ablation catheters for the treatment of persistent atrial fibrillation and ischaemic ventricular tachycardia.</p><p><strong>Design: </strong>Retrospective cohort.</p><p><strong>Setting: </strong>Three health systems in the USA.</p><p><strong>Participants: </strong>Patients receiving ablation with the two ablation catheters of interest at any of the three health systems.</p><p><strong>Main outcome measures: </strong>Feasibility of identifying the medical devices and participant populations of interest as well as the duration of follow-up and positive predictive values (PPVs) for serious safety (ischaemic stroke, acute heart failure and cardiac tamponade) and effectiveness (arrhythmia-related hospitalisation) clinical outcomes of interest compared with manual chart validation by clinicians.</p><p><strong>Results: </strong>Overall, the catheter of interest for treatment of persistent atrial fibrillation was used for 4280 ablations and the catheter of interest for ischaemic ventricular tachycardia was used 1516 times across the data available within the three health systems. The duration of patient follow-up in the three health systems ranged from 91% to 97% at ≥7 days, 89% to 96% at ≥30 days, 77% to 90% at ≥6 months and 66% to 84% at ≥1 year. PPVs were 63.4% for ischaemic stroke, 96.4% for acute heart failure, 100% at one health system for cardiac tamponade and 55.7% for arrhythmia-related hospitalisation.</p><p><strong>Conclusions: </strong>It is feasible to use real-world health system data to evaluate the safety and effectiveness of cardiac ablation catheters, though evaluations must consider the implications of variation in follow-up and endpoint ascertainment among health systems.</p>\",\"PeriodicalId\":33349,\"journal\":{\"name\":\"BMJ Surgery Interventions Health Technologies\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2021-12-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ce/79/bmjsit-2021-000089.PMC8749235.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Surgery Interventions Health Technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjsit-2021-000089\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Surgery Interventions Health Technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjsit-2021-000089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
Feasibility of using real-world data in the evaluation of cardiac ablation catheters: a test-case of the National Evaluation System for Health Technology Coordinating Center.
Objectives: To determine the feasibility of using real-world data to assess the safety and effectiveness of two cardiac ablation catheters for the treatment of persistent atrial fibrillation and ischaemic ventricular tachycardia.
Design: Retrospective cohort.
Setting: Three health systems in the USA.
Participants: Patients receiving ablation with the two ablation catheters of interest at any of the three health systems.
Main outcome measures: Feasibility of identifying the medical devices and participant populations of interest as well as the duration of follow-up and positive predictive values (PPVs) for serious safety (ischaemic stroke, acute heart failure and cardiac tamponade) and effectiveness (arrhythmia-related hospitalisation) clinical outcomes of interest compared with manual chart validation by clinicians.
Results: Overall, the catheter of interest for treatment of persistent atrial fibrillation was used for 4280 ablations and the catheter of interest for ischaemic ventricular tachycardia was used 1516 times across the data available within the three health systems. The duration of patient follow-up in the three health systems ranged from 91% to 97% at ≥7 days, 89% to 96% at ≥30 days, 77% to 90% at ≥6 months and 66% to 84% at ≥1 year. PPVs were 63.4% for ischaemic stroke, 96.4% for acute heart failure, 100% at one health system for cardiac tamponade and 55.7% for arrhythmia-related hospitalisation.
Conclusions: It is feasible to use real-world health system data to evaluate the safety and effectiveness of cardiac ablation catheters, though evaluations must consider the implications of variation in follow-up and endpoint ascertainment among health systems.